Understanding epigenetics: The potential rationale for BET inhibition in management of CVD

Understanding epigenetics The potential rationale for BET inhibition in management of CVD
10' education - Aug. 25, 2018 - ESC 2018 - Munich, Germany - Jorge Plutzky, MD – Boston, MA, USA
  • Overview

    Prof. Jorge Plutzky explains BET inhibition as a novel therapeutic strategy for controlling pathologic cardiovascular responses.

  • Educational information

    This lecture was part of a CME accredited symposium: "LDL-c: Done Deal, Next Epigenetics?" during ESC 2018 in Munich, Germany.

  • Faculty

    Jorge Plutzky, M.D. is Director, Preventive Cardiology at Brigham and Women’s Hospital (BWH), and is on the faculty of Harvard Medical School

  • Disclosures

    This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.

  • Funding

    Funding for this educational program was provided by an unrestricted educational grant from Resverlogix.

    The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Facebook Comments


We’re glad to see you’re enjoying PACE-CME…
but how about a more personalized experience?

Register for free